doxorubicin-analogues , with an overall in vitro efficacy in 16.0 % and 14.3 % for 4-epidoxorubicin ( epi-dx ) and 4-deoxydoxorubicin ( deo-dx ) , respectively , seem to deserve a modest role in the treatment of colorectal cancer , provided that a careful selection of patients is performed .
C0013089
doxorubicin
C0014582
epi-dx